Drug intelligence / Profile preview

Almega PL

Development stage: Unknown
Lead developer: alGeepa
Modality: Small Molecules
Administration: Oral

Overview

Almega PL is a vegan, microalgae-derived omega-3 dietary supplement ingredient extracted from *Nannochloropsis oculata*. Developed by Qualitas Health, it is uniquely characterized by a high concentration of eicosapentaenoic acid (EPA) (>25%) bound to polar lipids (phospholipids and glycolipids), with no docosahexaenoic acid (DHA). This polar lipid structure is similar to krill oil but is entirely plant-based and sustainable. It is primarily used for cardiovascular health support, specifically to manage cholesterol levels. Clinical studies have shown it significantly increases the Omega-3 Index and reduces VLDL-cholesterol and total cholesterol in healthy individuals. It was registered as a New Dietary Ingredient (NDIN) with the FDA in 2014.

Brand names: iWi
Other names: Nannochloropsis oculata oilEPA-rich polar lipid oil

Beyond the preview

Go deeper on Almega PL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Almega PL.

Explore the full profile